III Capital Management’s DexCom DXCM Stock Holding History

III Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300	Closed	-$11K	–	146
2022 Q2	$11K	Hold	300	–	–	﹤0.01%	164
2022 Q1	$225K	Buy	+300	New	+$32.8K	0.02%	122
2021 Q4	–	Sell	-300	Closed	-$251K	–	168
2021 Q3	$251K	Buy	+300	New	+$37.8K	0.02%	121

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

III Capital Management's DXCM Position: Q2 2022 in Review

III Capital Management sold out of DexCom (DXCM) in Q2 2022, closing a stake of 1,972 shares — an estimated $180K sold.

III Capital Management first reported a position in DXCM in Q3 2021 and held it in 2 quarters. The position peaked at $1.09M in Q3 2021. 797 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

III Capital Management reported no remaining DexCom position as of Q2 2022 after selling out during the quarter.
III Capital Management sold 1,972 DexCom shares in Q2 2022, an estimated $180K.
III Capital Management first reported a position in DexCom in Q3 2021 and held it in 2 quarters.
III Capital Management's DexCom position peaked at $1.09M in Q3 2021.
797 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on III Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.